HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00688324

Acamprosate and brain biomarkers in schizophrenia

About this titleRead the official source — NCT00688324
Medication studyAges 18–55United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Baltimore and 3 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 2008
Recruitment status
Completed
Enrollment listed in the registry
36
Sponsor
University of Maryland, Baltimore
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT00688324
Official title
Show the full official title

Biomarker Study of Acamprosate in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Baltimore

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Did this study involve medication?

Yes. The study involved medication, including Acamprosate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies